Financial Report: Amgen

Amgen
1Q Revenues: $5.6 billion(+2%)
1Q Earnings: $2.3 billion (+12%)
Comments: New and recently launched products performed well in the quarter. Repatha sales were up 151% to $123 million driven primarily by higher unit demand. KYPROLIS sales increased 17% to $222 million. Prolia sales increased 16% to $494 million. XGEVA sales increased 11% to $445 million. Sensipar/Mimpara sales increased 18% to $497 million. BLINCYTO sales increased 44% to $49 million. NEUPOGEN sales continued to decline, down 30% to $103 million due to increased competition. EPOGEN and Aranesp sales were also down 10% and 11% to $244 million and $454 million, respectively.